Rapamycin inhibits oxidative and angiogenic mediators in diabetic retinopathy

Canadian Journal of Ophthalmology

Volumn 49, Issue 5, 2014, Pages 443-449

  Ozdemir, Gökhan ^a   Kilinç, Metin ^a   Ergün, Yusuf ^b   Şahin, Elif ^a  

^a Department of Ophthalmology ^*  (United States)

^b KAHRAMANMARAS SUTCU IMAM UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ALBUMIN; CREATININE; HEMOGLOBIN A1C; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MALONALDEHYDE; PIGMENT EPITHELIUM DERIVED FACTOR; RAPAMYCIN; STREPTOZOCIN; VASCULOTROPIN; 3-NITROTYROSINE; ANGIOGENESIS MODULATOR; ANTIINFECTIVE AGENT; EYE PROTEIN; HIF1A PROTEIN, RAT; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ADULT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; INFECTION; LEUKOCYTE COUNT; LYMPHOCYTE; MALE; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; RAT; STREPTOZOTOCIN-INDUCED DIABETIC NEUROPATHY; WEAKNESS; ANALOGS AND DERIVATIVES; ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DRUG EFFECTS; METABOLISM; WISTAR RAT;

ANGIOGENESIS MODULATING AGENTS; ANIMALS; ANTI-BACTERIAL AGENTS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; EYE PROTEINS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MALONDIALDEHYDE; NERVE GROWTH FACTORS; OXIDATIVE STRESS; RATS; RATS, WISTAR; SERPINS; SIROLIMUS; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84925884070     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2014.07.003     Document Type: Article

References (45)

1. Stefansson E.Ocularoxygenationandthetreatmentofdiabetic retinopathy. Surv Ophthalmol. 2006;51:364-80.
2. Hammes HP,FengY,Pfister F,BrownleeM.Diabeticretinopathy: targeting vasoregression. Diabetes. 2011;60:9-16.
3. Curtis TM,GardinerTA,StittAW.Microvascularlesionsof diabetic retinopathy:cluestowardsunderstandingpathogenesis. Eye. 2009;23:1496-508.
4. Antonetti DA,BarberAJ,BronsonSK,etal.JDEFDiabetic Retinopathy CenterGroup.Diabeticretinopathy.Seeingbeyond glucose-induced microvasculardisease. Diabetes. 2006;55:2401-11.
5. Ozdemir G,TolunFI,GulM,ImrekS.Retinaloxidativestres induced byintraocularhypertensioninratsmaybeamelioratedby brimonidine treatmentandN-acetylcysteinesupplementation. J Glaucoma. 2009;18:662-5.
6. Kato N,YashimaS,SuzukiT,NakayamaY,JomoriT.Long-term treatment with fidarestat suppressesthedevelopmentofdiabetic retinopathy inSTZ-induceddiabeticrats. J DiabetesComplications. 2003;17:374-9.
7. Ellis EA,GuberskiDL,HutsonB,GrantMB.Timecourseof NADH oxidase,induciblenitricoxidesynthaseandperoxynitritein diabetic retinopathyintheBBZ/WORrat. Nitric Oxide. 2002;6:295-304.
8. Witmer AN,VrensenGFJM,vanNoordenCJF,SchlingemannRO. Vascular endothelialgrowthfactorsandangiogenesisineyedisease. Prog RetinEyeRes. 2003;22:1-29.
9. Penn JS,MadanA,CaldwellRB,BartoliM,CaldwellRW,Hartnett ME. Vascularendothelialgrowthfactorineyedisease. Prog RetinEye Res. 2008;27:331-71.
10. Provis JM.Developmentoftheprimateretinalvasculature. Prog Retin EyeRes. 2001;20:799-821.
11. Hudson CC,LiuM,ChiangGG,etal.Regulationofhypoxia-inducible factor1? expression andfunctionbythemammalian target ofrapamycin. Mol CellBiol. 2002;22:7004-14.
12. Kakehashi A,SaitoY,MoriK,etal.Characteristicsofdiabetic retinopathy inSDTrats. Diabetes MetabResRev. 2006;22:455-61.
13. Vezina C,KudelskiA,SehgalSN.Rapamycin(Ay-22,989),anew antifungal antibiotic.I.Taxonomyoftheproducingstreptomycete and isolationoftheactiveprinciple. J Antibiot(Tokyo). 1975;28: 721-6.
14. Guba M,vonBreitenbuchP,SteinbauerM,etal.Rapamycin inhibits primaryandmetastatictumorgrowthbyantiangiogenesis: involvement ofvascularendothelialgrowthfactor. Nat Med. 2002;8:128-35.
15. Maeda K,ShioiT,KosugiR,etal.Rapamycinameliorates experimental autoimmunemyocarditis. Int HeartJ. 2005;46: 513-30.
16. Iliaki E,PoulakiV,MitsiadesN,MitsiadesCS,MillerJW, Gragoudas ES.Roleof ?4 integrin(CD49d)inthepathogenesis of diabeticretinopathy. Invest OphthalmolVisSci. 2009;50: 4898-904.
17. Masuzawa K,JesminS,MaedaS,etal.Effectofendothelindual receptor antagonistonVEGFlevelsinstreptozotocin-induced diabetic ratretina. Exp BiolMed(Maywood). 2006;23:1090-4.
18. Ohkawa H,OhishiN,YagiK.Assayforlipidperoxidesinanimal tissues bythiobarbituricacidreaction. Anal Biochem. 1979;95: 351-8.
19. Lowry OH,RosebroughNJ,FarrAL,RandaiiRJ.Proteinmeasure-ment withtheFolinphenolreagent. J BiolChem. 1951;193:265-75.
20. Arnal E,MirandaM,Johnsen-SorianoS.Beneficial effectof docosahexanoic acidandluteinonretinalstructural,metabolic, and functionalabnormalitiesindiabeticrats. Curr EyeRes. 2009; 34:928-38.
21. El-Remessy AB,BehzadianMA,Abou-MohamedG,FranklinT, Caldwell RW,CaldwellRB.Experimentaldiabetescausesbreak-down oftheblood-retinabarrierbyamechanisminvolvingtyrosine nitration andincreasesinexpressionofvascularendothelialgrowth factor andurokinaseplasminogenactivatorreceptor. Am JPathol. 2003;162:1995-2004.
22. Cai J,BoultonM.Thepathogenesisofdiabeticretinopathy:old concepts andnewquestions. Eye. 2002;16:242-60.
23. Arjamaa O,NikinmaaM.Oxygen-dependentdiseasesintheretina: role ofhypoxia-induciblefactor. Exp EyeRes. 2006;83:473-83.
24. Du Y,SmithMA,MillerCM,KernTS.Diabetesinducednitrative stress intheretina,andcorrectionbyaminoguanidine. J Neurochem. 2002;80:771-9.
25. Hardy P,DumontI,BhattacharyaM,etal.Oxidants,nitricoxide and prostanoidsinthedevelopingocularvasculature:abasisfor ischemic retinopathy. Cardiovasc Res. 2000;47:489-509.
26. Quijano C,RomeroN,RadiR.Tyrosinenitrationbysuperoxide and nitricoxide fluxes inbiologicalsystems:modelingtheimpactof superoxide dismutaseandnitricoxidediffusion. Free RadicBiolMed. 2005;39:728-41.
27. Yilmaz G,EsserP,KociekN,AydinP,HeimannK.Elevated vitreous nitricoxidelevelsinpatientswithproliferativediabetic retinopathy. Am JOphthalmol. 2000;130:87-90.
28. Liu YX,JinLM,ZhouL,etal.Sirolimusattenuatesreduced-size liver ischemia-reperfusion injurybutimpairsliverregenerationin rats. Dig DisSci. 2010;55:2255-62.
29. Chauhan A,SharmaU,JagannathanNR,ReetaKH,GuptaYK. Rapamycin protectsagainstmiddlecerebralarteryocclusioninduced focal cerebralischemiainrats. Behav BrainRes. 2011;225:603-9.
30. Bandello F,MenchiniF.Newinsightsintothepathogenesisof diabetic retinopathy. Johns HopkinsAdvStudOphthalmol. 2008;5: 16-21.
31. Kowluru RA,MenonB,GierhartDL.Beneficial effectofzeaxanthin on retinalmetabolicabnormalitiesindiabeticrats. Invest Ophthalmol Vis Sci. 2008;49:1645-51.
32. Asnaghi L,BrunoP,PriullaM,NicolinA.mTOR:aproteinkinase switching betweenlifeanddeath. Pharmacol Res. 2004;50:545-9.
33. Koehl G,GubaM,SeeligerH,etal.Rapamycintreatmentat immunosuppressive dosesaffectstumorbloodvesselcirculation. Transplant Proc. 2003;35:2135-6.
34. Harrison DE,StrongR,SharpZD,etal.Rapamycinfedlateinlife extends lifespaningeneticallyheterogeneousmice. Nature. 2009;460:392-6.
35. Sehgal SN.Sirolimus:itsdiscovery,biologicalproperties,and mechanism ofaction. Transplant Proc. 2003;35(Suppl):7S-14S.
36. Hughes JM,GrootAJ,vanderGroepP,etal.ActiveHIF-1inthe normal humanretina. J HistochemCytochem. 2010;58:247-54.
37. Miller JW,LeCouterJ,StraussEC,FerraraN.Vascularendothelial growth factorAinintraocularvasculardisease. Ophthalmology. 2013;120:106-14.
38. HofmanP,vanBlijswijkBC,GaillardPJ,VrensenGFJM,Schlinge-mannRO.Endothelialcellhypertrophyinducedbyvascularendo-thelialgrowthfactorintheretina.Newinsightsintothepathogenesis of capillarynonperfusion. ArchOphthalmol. 2001;119:861-6.
39. Hofman P,BlaauwgeersHGT,VrensenGFJM,SchlingemannRO. Role ofVEGF-Ainendothelialphenotypicshiftinhumandiabetic retinopathy andVEGF-A-inducedretinopathyinmonkeys. Oph-thalmic Res. 2001;33:156-62.
40. Wang B,AthertonP,PatelR,ManningG,DonnellyR.Antiangio-genic effectsandtranscriptionalregulationofPEDFindiabetic retinopathy. Microvasc Res. 2010;80:31-6.
41. Boehm BO,LangG,VolpertO,etal.Lowcontentofthenatural ocular anti-angiogenicagentpigmentepithelium-derivedfactor (PEDF) inaqueoushumorpredictsprogressionofdiabeticretinop-athy. Diabetologia. 2003;46:394-400.
42. Matsuoka M,OgataN,MinaminoK,HiguchiA,MatsumuraM. High levelsofpigmentepithelium-derivedfactorintheretinaofa rat modeloftype2diabetes. Exp EyeRes. 2006;82:172-8.
43. Weinreich J,LöbS,Löffler M,etal.Rapamycininducedimpaired wound healingisassociatedwithcompromisedtissuelactate accumulation andextracellularmatrixremodeling. Eur SurgRes. 2011;47:39-44.
44. Dejneka NS,KurokiAM,FosnotJ,TangW,TolentinoMJ,Bennet J. Systemicrapamycininhibitsretinalandchoroidalneovasculariza-tion inmice. Mol Vis. 2004;10:964-72.
45. Gologorsky D,ThanosA,VavvasD.Therapeuticinterventions against inflammatory andangiogenicmediatorsinproliferative diabetic retinopathy. Mediators Inflamm. 2012;2012:629452.